General MedicationsINTRAVENOUSStandard
PYLARIFY
PIFLUFOLASTAT F-18
Standard Dose
50ML (1-80mCi/ML)
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Prescription
Summary
Approval overview PYLARIFY is listed in Drugs@FDA under application 214793 (NDA).
Review priority: PRIORITY Marketing status: Prescription Active ingredient PIFLUFOLASTAT F-18 Form and strength SOLUTION;INTRAVENOUS - 50ML (1-80mCi/ML) Sponsor PROGENICS PHARMS INC Submission history Latest submission status date: 2021-05-26 00:00:00.
Structured Monograph
Clinical summary
Approval overview PYLARIFY is listed in Drugs@FDA under application 214793 (NDA). Review priority: PRIORITY Marketing status: Prescription Active ingredient PIFLUFOLASTAT F-18 Form and strength SOLUTION;INTRAVENOUS - 50ML (1-80mCi/ML) Sponsor PROGENICS PHARMS INC Submission history Latest submission status date: 2021-05-26 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: PRIORITY
Interaction Notes
- No interaction notes stored yet.